HIMR, page-6

"A method of treating inflammation in an individual comprising, consisting essentially of or consisting of the steps of:
administering a therapeutically effective amount of idronoxil, or derivative, pharmaceutically acceptable salt, ester, amide, polymorph and/or prodrug thereof to the individual;
wherein administration is prior to late stage organ damage caused by inflammation associated with infection,
thereby treating the inflammation."

"therapeutically effective amount of idronoxil" of course it got knocked back with such shooting for the moon statements.

see further in the description.....

"Typically, a therapeutically effective dosage is formulated to contain a concentration (by weight) of at least about 0.1% up to about 50% or more, and all combinations and sub-combinations of ranges therein"

The frequency of administration may be once daily, or 2 or 3 time daily. The treatment period may be for the duration of the detectable disease. Preferably, the treatment is for a period of 14 to 28 days.

and

"Compositions of the invention may be administered orally, nasally, intravenously, intramuscularly, topically, subcutaneously, rectally, vaginally or by urethral application. Preferably, compositions of the invention are administered rectally, vaginally or by urethral application."

Why don't they just say we claim all IP to idronoxil and its methods of us.